Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $13.0 million.

  • Maxcyte's Cash & Equivalents fell 6489.8% to $13.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 million, marking a year-over-year decrease of 6489.8%. This contributed to the annual value of $27.9 million for FY2024, which is 4004.21% down from last year.
  • Maxcyte's Cash & Equivalents amounted to $13.0 million in Q3 2025, which was down 6489.8% from $15.2 million recorded in Q2 2025.
  • In the past 5 years, Maxcyte's Cash & Equivalents registered a high of $239.8 million during Q1 2022, and its lowest value of $11.1 million during Q4 2022.
  • For the 5-year period, Maxcyte's Cash & Equivalents averaged around $50.6 million, with its median value being $37.7 million (2023).
  • Over the last 5 years, Maxcyte's Cash & Equivalents had its largest YoY gain of 32029.82% in 2023, and its largest YoY loss of 8422.14% in 2023.
  • Over the past 5 years, Maxcyte's Cash & Equivalents (Quarter) stood at $47.8 million in 2021, then crashed by 76.84% to $11.1 million in 2022, then skyrocketed by 320.3% to $46.5 million in 2023, then tumbled by 40.04% to $27.9 million in 2024, then plummeted by 53.48% to $13.0 million in 2025.
  • Its last three reported values are $13.0 million in Q3 2025, $15.2 million for Q2 2025, and $23.4 million during Q1 2025.